US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

BridgeBio Oncology Therapeutics, Inc

10.15

+0.17001.70%

Volume:359.45K

Turnover:3.61M

Market Cap:811.89M

PE:-0.98

High:10.33

Open:9.93

Low:9.87

Close:9.98

52wk High:14.87

52wk Low:8.50

Shares:79.99M

Float Shares:44.60M

Volume Ratio:1.16

T/O Rate:0.81%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-10.3075

EPS(LYR):-511.8002

ROE:--

ROA:--

PB:1.82

PE(LYR):-0.02

Loading ...

Overview Company News Filings

BridgeBio Oncology Therapeutics to Present at Major Healthcare Investor Conferences

BridgeBio Oncology Therapeutics Grants Stock Options Under 2025 Inducement Plan

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Oncology Initiated at Buy by Stifel

BridgeBio Oncology Therapeutics Inc : Stifel Initiates Coverage With Buy Rating; Price Target $23

THOMSON REUTERS

U.S. RESEARCH ROUNDUP-KKR, Sirius XM, Workday

BridgeBio Oncology Therapeutics Inc : Leerink Partners Raises Target Price to $41 From $32

THOMSON REUTERS

BridgeBio Oncology Therapeutics Grants Inducement Stock Options Under 2025 Plan

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Oncology price target lowered to $18 from $20 at Morgan Stanley

BridgeBio Oncology Therapeutics (BBOT) Receives a Buy from Piper Sandler

Bbot Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated Ras and Pi3kΑ Pipeline Programs

THOMSON REUTERS

BridgeBio Oncology Reports Positive Early Results for Three RAS and PI3Kα Cancer Therapies

BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs

BridgeBio Oncology Therapeutics to Present at J.P. Morgan Healthcare Conference

BridgeBio Oncology Therapeutics Grants Stock Options Under New Inducement Plan

BridgeBio Oncology Price Target Maintained With a $25.00/Share by Wedbush

BridgeBio Oncology Therapeutics Launches Phase 1 Trial of BBO-10203 in Advanced Solid Tumors

Bbot Announces Late-Breaking Preclinical Data on Bbo-10203, a First-in-Class Ras:Pi3kΑ Breaker, at the San Antonio Breast Cancer Symposium (Sabcs)

THOMSON REUTERS

BridgeBio Oncology Initiated at Overweight by Morgan Stanley

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BBOT/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BBOT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBOT\",,,,,undefined,":{"symbol":"BBOT","market":"US","secType":"STK","nameCN":"BridgeBio Oncology Therapeutics, Inc","latestPrice":10.15,"timestamp":1771880400000,"preClose":9.98,"halted":0,"volume":359447,"delay":0,"changeRate":0.017034068136272538,"floatShares":44603977,"shares":79988687,"eps":-10.307472,"marketStatus":"Pre-Mkt","change":0.17,"latestTime":"02-24 05:35:02 EST","open":9.93,"high":10.33,"low":9.87,"amount":3612833.643735,"amplitude":0.046092,"askPrice":16.24,"askSize":200,"bidPrice":4.06,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-10.307472,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1771943400000},"marketStatusCode":1,"adr":0,"listingDate":1707454800000,"exchange":"NASDAQ","adjPreClose":10.15,"postHourTrading":{"tag":"盘后","latestPrice":10.15,"preClose":10.15,"latestTime":"16:10 EST","volume":337,"amount":3420.55,"timestamp":1771881004529,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.1602411648681383},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBOT\",,,,,undefined,":{"symbol":"BBOT","floatShares":44603977,"roa":"--","roe":"--","lyrEps":-511.800172,"volumeRatio":1.1602411648681383,"shares":79988687,"dividePrice":0,"high":10.33,"amplitude":0.046092,"preClose":9.98,"low":9.87,"week52Low":8.5,"pbRate":"1.82","week52High":14.87,"institutionHeld":0,"latestPrice":10.15,"eps":-10.307472,"divideRate":0,"volume":359447,"delay":0,"ttmEps":-10.307472,"open":9.93,"prevYearClose":12.52,"prevWeekClose":9.98,"prevMonthClose":11.72,"prevQuarterClose":12.52,"fiveDayClose":11.25,"twentyDayClose":12.62,"sixtyDayClose":12.29},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BBOT\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-12","symbol":"BBOT","fiscalQuarterEnding":"2025/09","expectedEps":-0.41,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"post","actualEps":-1.03},{"market":"US","date":"2025-08-01","symbol":"BBOT","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754020800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-05-15","symbol":"BBOT","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-11-14","symbol":"BBOT","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BBOT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BBOT\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4444,"buy":0.5556,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5556,"analysts":9,"updateTime":1770958800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BBOT\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BBOT","date":"2026-02-20","current":-0.984723,"percent":1,"low":-11.944957,"twenty":-10.812388,"median":-9.272371,"eighty":-8.35979,"high":-7.043047,"avg":-9.416804,"sd":1.239625,"marketCap":809485512},"quantilePoints":[{"date":"2025-08-22","current":-9.544109,"twenty":-10.820609,"median":-9.81087,"eighty":-9.532253,"marketCap":835109579},{"date":"2025-08-29","current":-9.336629,"twenty":-9.787158,"median":-9.514469,"eighty":-9.277349,"marketCap":816955023},{"date":"2025-09-05","current":-9.959071,"twenty":-9.864223,"median":-9.514469,"eighty":-9.247708,"marketCap":871418691},{"date":"2025-09-12","current":-10.047991,"twenty":-10.065775,"median":-9.65773,"eighty":-9.388005,"marketCap":879199215},{"date":"2025-09-19","current":-10.690193,"twenty":-10.20212,"median":-9.78123,"eighty":-9.467045,"marketCap":935391888},{"date":"2025-09-26","current":-11.678196,"twenty":-11.017222,"median":-9.944251,"eighty":-9.487793,"marketCap":1021842155},{"date":"2025-10-03","current":-11.259509,"twenty":-11.190123,"median":-10.077631,"eighty":-9.526325,"marketCap":985207072},{"date":"2025-10-10","current":-11.196152,"twenty":-11.224546,"median":-10.323455,"eighty":-9.563869,"marketCap":979663302},{"date":"2025-10-17","current":-10.3182,"twenty":-11.192532,"median":-10.372506,"eighty":-9.601414,"marketCap":902842494},{"date":"2025-10-24","current":-9.838494,"twenty":-11.156298,"median":-10.223893,"eighty":-9.601414,"marketCap":860868237},{"date":"2025-10-31","current":-10.861263,"twenty":-11.08659,"median":-10.23674,"eighty":-9.656742,"marketCap":950360520},{"date":"2025-11-07","current":-11.087539,"twenty":-11.118284,"median":-10.345353,"eighty":-9.745662,"marketCap":970159697},{"date":"2025-11-14","current":-11.205203,"twenty":-11.201583,"median":-10.472068,"eighty":-9.804136,"marketCap":980455269},{"date":"2025-11-21","current":-8.47671,"twenty":-11.192532,"median":-10.345353,"eighty":-9.572151,"marketCap":974262207},{"date":"2025-11-28","current":-8.567184,"twenty":-11.17443,"median":-10.251046,"eighty":-9.478901,"marketCap":984660736},{"date":"2025-12-05","current":-8.0313,"twenty":-11.121014,"median":-10.182434,"eighty":-9.298176,"marketCap":923069447},{"date":"2025-12-12","current":-8.936039,"twenty":-11.105583,"median":-10.084778,"eighty":-9.061365,"marketCap":1027054741},{"date":"2025-12-19","current":-8.389716,"twenty":-11.080298,"median":-9.97426,"eighty":-8.826299,"marketCap":964263621},{"date":"2025-12-26","current":-8.490629,"twenty":-11.051335,"median":-9.938056,"eighty":-8.720294,"marketCap":975861981},{"date":"2026-01-02","current":-8.713334,"twenty":-11.00789,"median":-9.919954,"eighty":-8.650698,"marketCap":1001458361},{"date":"2026-01-09","current":-9.256178,"twenty":-10.960825,"median":-9.809862,"eighty":-8.597806,"marketCap":1063849537},{"date":"2026-01-16","current":-8.003462,"twenty":-10.901088,"median":-9.61327,"eighty":-8.567184,"marketCap":919869900},{"date":"2026-01-23","current":-7.829474,"twenty":-10.885701,"median":-9.557912,"eighty":-8.530995,"marketCap":899872728},{"date":"2026-01-30","current":-8.699415,"twenty":-10.880305,"median":-9.521034,"eighty":-8.553265,"marketCap":999858587},{"date":"2026-02-06","current":-7.063925,"twenty":-10.867923,"median":-9.470009,"eighty":-8.485061,"marketCap":811885173},{"date":"2026-02-13","current":-7.947786,"twenty":-10.83411,"median":-9.398729,"eighty":-8.38554,"marketCap":913470805},{"date":"2026-02-20","current":-7.043047,"twenty":-10.812388,"median":-9.272371,"eighty":-8.35979,"marketCap":809485512}],"updateTime":1771900300156},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BBOT\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2611977428","title":"BridgeBio Oncology Therapeutics to Present at Major Healthcare Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2611977428","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611977428?lang=en_us&edition=fundamental","pubTime":"2026-02-13 05:05","pubTimestamp":1770930319,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bridgebio Oncology Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on February 12, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nNDL8zm7vq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","IE00B3QW5Z07.USD","BBIO","SG9999014021.USD","IE00BKPKM429.USD","BK4585","BK4588","BK4505","BBOT","SG9999014013.SGD","IE00BGHQF748.EUR","LU0314104364.USD","NDAQ","SG9999014039.USD","BK4139","IE00B64PRP62.GBP","LU2210150020.SGD","LU2095319765.USD","BK4112","SG9999014005.SGD"],"gpt_icon":0},{"id":"2610965072","title":"BridgeBio Oncology Therapeutics Grants Stock Options Under 2025 Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2610965072","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610965072?lang=en_us&edition=fundamental","pubTime":"2026-02-12 05:05","pubTimestamp":1770843909,"startTime":"0","endTime":"0","summary":"BridgeBio Oncology Therapeutics Inc. has announced the grant of inducement stock options to two newly hired employees. The awards, totaling options to purchase 65,350 shares of BBOT common stock at an exercise price of $10.84 per share, will vest 25% on the first anniversary of each employee’s start date, with the remaining shares vesting in 36 equal monthly installments thereafter, contingent on continued employment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bridgebio Oncology Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on February 11, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nNDL8x8LjJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","LU2095319765.USD","LU0314104364.USD","BBIO","LU2210150020.SGD","IE00B64PRP62.GBP","SG9999014013.SGD","BK4139","SG9999014021.USD","BBOT","SG9999014039.USD","BK4585","LU2210149790.SGD","BK4112","IE00BGHQF748.EUR","BK4505","SG9999014005.SGD","BK4588","IE00BKPKM429.USD","NDAQ"],"gpt_icon":0},{"id":"2610964216","title":"BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2610964216","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610964216?lang=en_us&edition=fundamental","pubTime":"2026-02-12 05:05","pubTimestamp":1770843900,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Feb.  11, 2026  (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malign","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/11/3236652/0/en/BridgeBio-Oncology-Therapeutics-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBOT","BK4139","BK4007","BK4539","LENZ"],"gpt_icon":0},{"id":"2610594969","title":"BridgeBio Oncology Initiated at Buy by Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2610594969","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610594969?lang=en_us&edition=fundamental","pubTime":"2026-02-11 23:17","pubTimestamp":1770823020,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BBOT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 11, 2026 10:17 ET (15:17 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBOT","BK4127","SF","BK4139"],"gpt_icon":0},{"id":"2610315929","title":"BridgeBio Oncology Therapeutics Inc : Stifel Initiates Coverage With Buy Rating; Price Target $23","url":"https://stock-news.laohu8.com/highlight/detail?id=2610315929","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610315929?lang=en_us&edition=fundamental","pubTime":"2026-02-11 19:42","pubTimestamp":1770810162,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nFWN3Z70VU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BBOT"],"gpt_icon":0},{"id":"2610614501","title":"U.S. RESEARCH ROUNDUP-KKR, Sirius XM, Workday","url":"https://stock-news.laohu8.com/highlight/detail?id=2610614501","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610614501?lang=en_us&edition=fundamental","pubTime":"2026-02-10 15:58","pubTimestamp":1770710313,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-KKR, Sirius XM, Workday Feb 10 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including KKR, Sirius XM Hold","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nL4N3Z60LE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMS","GPI","FTAI","PANW","MCK","BAM","RGNX","FLNC","AFG","AMKR","LU0683600562.USD","CRCA","EXEL","LU2360107671.USD","NUVL","ARVN","ARES","CAH","COR","DVN","LU0310800965.SGD","GPOR","APA","CCUP","ICHR","MNST","BX","CRCL","CELC","SIRI","LPLA","KD","CRCG","KKR","IE00B19Z4B17.USD","APO","LU2360107325.USD","EXE","CRCD","LU0203345920.USD","BBOT","RAL","COGT","DT","FANG","CRCO","BDX","GLTO","CGEM"],"gpt_icon":0},{"id":"2610690282","title":"BridgeBio Oncology Therapeutics Inc : Leerink Partners Raises Target Price to $41 From $32","url":"https://stock-news.laohu8.com/highlight/detail?id=2610690282","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610690282?lang=en_us&edition=fundamental","pubTime":"2026-02-10 13:47","pubTimestamp":1770702466,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nFWN3Z603G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BBOT"],"gpt_icon":0},{"id":"2603663002","title":"BridgeBio Oncology Therapeutics Grants Inducement Stock Options Under 2025 Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2603663002","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603663002?lang=en_us&edition=fundamental","pubTime":"2026-01-14 05:05","pubTimestamp":1768338313,"startTime":"0","endTime":"0","summary":"BridgeBio Oncology Therapeutics Inc. has announced the granting of non-qualified stock options to a newly hired employee. The grant covers 129,090 shares of BBOT common stock at an exercise price of $13.19 per share, matching the company’s closing price on the grant date. The options will vest with one quarter becoming available on the first anniversary of the employee’s start date, and the remainder vesting in 36 equal monthly installments, contingent on continued employment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bridgebio Oncology Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on January 13, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nNDL2fndr8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0314104364.USD","SG9999014013.SGD","LU2210150020.SGD","IE00B64PRP62.GBP","BBIO","SG9999014005.SGD","IE00BKPKM429.USD","SG9999014021.USD","IE00B3QW5Z07.USD","BK4112","BK4139","SG9999014039.USD","BBOT","LU2210149790.SGD","BK4505","BK4588","NDAQ","IE00BGHQF748.EUR","LU2095319765.USD"],"gpt_icon":0},{"id":"2603865840","title":"BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2603865840","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603865840?lang=en_us&edition=fundamental","pubTime":"2026-01-14 05:05","pubTimestamp":1768338300,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Jan.  13, 2026  (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malign","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/13/3218252/0/en/BridgeBio-Oncology-Therapeutics-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BBOT","LENZ","BK4139","BK4007"],"gpt_icon":0},{"id":"2601583364","title":"BridgeBio Oncology price target lowered to $18 from $20 at Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2601583364","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601583364?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:51","pubTimestamp":1767876672,"startTime":"0","endTime":"0","summary":"Morgan Stanley lowered the firm’s price target on BridgeBio Oncology (BBOT) to $18 from $20 and keeps an Overweight rating on the shares. The firm ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bridgebio-oncology-price-target-lowered-to-18-from-20-at-morgan-stanley-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bridgebio-oncology-price-target-lowered-to-18-from-20-at-morgan-stanley-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2347655156.SGD","BBOT","BK4139","LU0971096721.USD","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU0106831901.USD","LU0314104364.USD","LU0158827781.USD","LU1548497426.USD","LU0225283273.USD","LU0528227936.USD","LU0912757837.SGD","LU1244550577.SGD","LU1720051108.HKD","LU0557290698.USD","BK4585","BK4588","LU0158827948.USD","LU1732800096.USD","BK4504","LU1074936037.SGD","BK4581","LU2089284900.SGD","LU0098860793.USD","BK4516","LU1244550494.USD","BK4127","LU2089283258.USD","LU2271345857.HKD","LU2028103732.USD","LU0267386448.USD","LU1363072403.SGD","LU0795875086.SGD","LU1244550221.USD","LU1720051017.SGD","LU1732799900.SGD","LU1162221912.USD","LU1989772840.SGD","BK4534","LU0006306889.USD","LU1668664300.SGD","LU0882574139.USD","LU1791710400.SGD","LU2111349929.HKD","LU0106261372.USD","LU2023251221.USD","LU2133065610.SGD","LU0234570918.USD","LU0795875169.SGD"],"gpt_icon":0},{"id":"2601369952","title":"BridgeBio Oncology Therapeutics (BBOT) Receives a Buy from Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2601369952","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601369952?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:17","pubTimestamp":1767874661,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst Biren Amin maintained a Buy rating on BridgeBio Oncology Therapeutics today and set a price target of $21.00. According to Ti...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bridgebio-oncology-therapeutics-bbot-receives-a-buy-from-piper-sandler-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bridgebio-oncology-therapeutics-bbot-receives-a-buy-from-piper-sandler-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBOT","BK4139"],"gpt_icon":0},{"id":"2601870554","title":"Bbot Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated Ras and Pi3kΑ Pipeline Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2601870554","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601870554?lang=en_us&edition=fundamental","pubTime":"2026-01-07 20:04","pubTimestamp":1767787440,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nFWN3Y7187:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BBOT","BK4139"],"gpt_icon":0},{"id":"2601338870","title":"BridgeBio Oncology Reports Positive Early Results for Three RAS and PI3Kα Cancer Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2601338870","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601338870?lang=en_us&edition=fundamental","pubTime":"2026-01-07 20:00","pubTimestamp":1767787232,"startTime":"0","endTime":"0","summary":"BridgeBio Oncology Therapeutics Inc.  announced positive preliminary safety and antitumor data from clinical studies across its three orally bioavailable small molecule RAS and PI3Kα programs. Results were presented for BBO-8520, a direct KRASG12C inhibitor, which showed a 65% objective response rate and a 66% 6-month progression-free survival in KRASG12C non-small cell lung cancer patients. Early efficacy was also observed in patients with KRASG12C and STK11 and/or KEAP1 co-mutations. Combination studies of BBO-8520 with pembrolizumab indicated promising efficacy and a differentiated safety profile. BBO-11818, a panKRAS inhibitor, demonstrated a confirmed partial response in pancreatic cancer and observed anti-tumor activity across multiple tumor types at higher dose levels. BBO-10203, a RAS-PI3Kα breaker, showed a differentiated safety profile and no observed hyperglycemia; combination studies with standard-of-care treatments in colorectal and breast cancer have been initiated, and i","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL9nvHdZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","SG9999014021.USD","SG9999014039.USD","IE00B3QW5Z07.USD","LU2095319765.USD","BK4139","BK4112","LU0314104364.USD","IE00BKPKM429.USD","BK4588","IE00BGHQF748.EUR","BK4585","IE00B64PRP62.GBP","LU2210149790.SGD","LU2210150020.SGD","SG9999014005.SGD","SG9999014013.SGD","BBOT"],"gpt_icon":0},{"id":"2601870204","title":"BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2601870204","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601870204?lang=en_us&edition=fundamental","pubTime":"2026-01-07 20:00","pubTimestamp":1767787200,"startTime":"0","endTime":"0","summary":"BBO-8520 monotherapy in patients withKRASG12C non-small cell lung cancer (NSCLC) showed a 65% objective response rate (ORR) and a 66% 6-month progression-free survival (PFS), with 83% of patients elig","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/07/3214384/0/en/BBOT-Announces-New-Clinical-Data-Advancing-Its-Portfolio-of-Three-Innovative-and-Differentiated-RAS-and-PI3K%CE%B1-Pipeline-Programs.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","SOC","BK4581","BK4213","BK4181","ET","BK4561","PR","CRC","LU0266512127.USD","BK4195","BK4144","BK4590","BK4161","CR","BK4211","BBOT","BK4190","BC","BK4588","LU0456854461.SGD","PFS","BK4139","BK4218","PK","ORR"],"gpt_icon":0},{"id":"2592916937","title":"BridgeBio Oncology Therapeutics to Present at J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2592916937","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592916937?lang=en_us&edition=fundamental","pubTime":"2025-12-17 05:05","pubTimestamp":1765919109,"startTime":"0","endTime":"0","summary":"BridgeBio Oncology Therapeutics Inc.  will participate in a presentation at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 5:15 p.m. PT. The event will feature a live webcast accessible on the BBOT website, with a replay available for at least 90 days following the presentation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bridgebio Oncology Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on December 16, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nNDL1X2nJP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","BK4585","IE00B3QW5Z07.USD","LU2210149790.SGD","IE00BKPKM429.USD","NDAQ","SG9999014039.USD","IE00B64PRP62.GBP","BBIO","BK4588","BK4505","BK4112","BBOT","SG9999014005.SGD","SG9999014021.USD","LU0314104364.USD","LU2095319765.USD","BK4139","SG9999014013.SGD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2590491135","title":"BridgeBio Oncology Therapeutics Grants Stock Options Under New Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2590491135","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590491135?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:05","pubTimestamp":1765487110,"startTime":"0","endTime":"0","summary":"BridgeBio Oncology Therapeutics Inc. has awarded a new inducement grant to an employee hired in November 2025. The grant consists of non-qualified stock options to purchase 53,060 shares of BBOT common stock at an exercise price of $12.88 per share, the closing price on the grant's effective date. The options will vest 25% on the first anniversary of the employee's start date, with the remaining shares vesting in 36 equal monthly installments thereafter, contingent on continued employment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bridgebio Oncology Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on December 11, 2025, and is solely responsible for the information contained there","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL8mqGnx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","SG9999014013.SGD","BBIO","BBOT","LU2210150020.SGD","BK4112","LU2210149790.SGD","BK4505","IE00B64PRP62.GBP","LU0314104364.USD","LU2095319765.USD","BK4585","SG9999014005.SGD","SG9999014039.USD","BK4139","IE00BKPKM429.USD","IE00BGHQF748.EUR","BK4588","SG9999014021.USD","NDAQ"],"gpt_icon":0},{"id":"2590351421","title":"BridgeBio Oncology Price Target Maintained With a $25.00/Share by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2590351421","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590351421?lang=en_us&edition=fundamental","pubTime":"2025-12-11 22:39","pubTimestamp":1765463940,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BBOT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 11, 2025 09:39 ET (14:39 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBOT","BK4139"],"gpt_icon":0},{"id":"2590130558","title":"BridgeBio Oncology Therapeutics Launches Phase 1 Trial of BBO-10203 in Advanced Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2590130558","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590130558?lang=en_us&edition=fundamental","pubTime":"2025-12-11 05:05","pubTimestamp":1765400716,"startTime":"0","endTime":"0","summary":"BridgeBio Oncology Therapeutics Inc. announced late-breaking preclinical data on BBO-10203, a first-in-class covalent small molecule RAS:PI3Kα breaker, at the San Antonio Breast Cancer Symposium . The preclinical data demonstrated that BBO-10203 blocks RAS-mediated activation of PI3Kα, inhibits pAKT signaling in tumor cells without inducing hyperglycemia, and shows anti-tumor activity both as monotherapy and in combination with standard therapies in breast cancer models. The company also presented information regarding the Phase 1 BREAKER-101 clinical trial , which is currently enrolling patients with locally advanced or metastatic HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer in the United States and Australia. Initial Phase 1 clinical data from the BREAKER-101 trial are expected in the first half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. Wh","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDL9wdQ8p:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","SG9999014005.SGD","SG9999014013.SGD","BK4505","BK4588","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","SG9999014021.USD","BK4139","IE00B64PRP62.GBP","BK4585","LU2210150020.SGD","LU2095319765.USD","IE00BKPKM429.USD","BK4112","LU0314104364.USD","BBIO","BBOT","SG9999014039.USD","NDAQ"],"gpt_icon":0},{"id":"2590655896","title":"Bbot Announces Late-Breaking Preclinical Data on Bbo-10203, a First-in-Class Ras:Pi3kΑ Breaker, at the San Antonio Breast Cancer Symposium (Sabcs)","url":"https://stock-news.laohu8.com/highlight/detail?id=2590655896","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590655896?lang=en_us&edition=fundamental","pubTime":"2025-12-11 05:05","pubTimestamp":1765400700,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nTUA8N23J8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BBOT","BK4139"],"gpt_icon":0},{"id":"2589168868","title":"BridgeBio Oncology Initiated at Overweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2589168868","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589168868?lang=en_us&edition=fundamental","pubTime":"2025-12-05 23:32","pubTimestamp":1764948720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BBOT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 05, 2025 10:32 ET (15:32 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BBOT"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":41,"code":"91000000","status":"200"}]}}